KemPharm partners with Hypersomnia Foundation

KemPharm announced its partnership with the Hypersomnia Foundation, which engages, informs and champions the global community to improve the lives of people with idiopathic hypersomnia and related sleep disorders. IH is a chronic neurologic disorder marked by significant detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness. It is estimated that approximately 37,000 patients are currently diagnosed with IH and seeking treatment, although the total population may be much larger due to patients not seeking treatment or having not been diagnosed. KemPharm is currently investigating KP1077 in a double-blind, placebo-controlled, randomized-withdrawal, dose-optimizing, multi-center Phase 2 clinical trial evaluating the efficacy and safety of KP1077 for the treatment of IH. KemPharm expects to enroll approximately 48 adult patients with IH in more than 30 centers in the United States.